Literature DB >> 30951438

Ligaments and Lymphatic Pathways in Gastric Adenocarcinoma.

Jennifer J Young1, Anokh Pahwa1, Maitraya Patel1, Cecilia M Jude1, Michael Nguyen1, Monica Deshmukh1, Lizhou Huang1, Shaden F Mohammad1.   

Abstract

Gastric cancer is a leading cause of cancer-related deaths worldwide and is associated with an overall 5-year survival rate of less than 20%. The most common histologic subtype of gastric cancer is adenocarcinoma. Imaging techniques for evaluating gastric adenocarcinoma include endoscopic US, fluoroscopic upper gastrointestinal imaging, CT, PET/CT, and MRI. Hydrodynamic multiphasic contrast material-enhanced CT is the imaging modality of choice for preoperative clinical staging of regional, nodal, and metastatic involvement. Radiologic manifestations of gastric adenocarcinoma at double-contrast upper gastrointestinal imaging and CT include polyps, ulceration, indistensibility, wall thickening, and abnormal enhancement. There are multiple pathways of disease spread. These pathways include lymphatic dissemination; subperitoneal dissemination along the perigastric ligaments, mesentery, or omentum; direct invasion into adjacent organs; transperitoneal seeding; and hematogenous dissemination. The spread of disease is affected by the location of the tumor in the stomach, and the ligamentous and lymphatic anatomy. Key imaging features that affect clinical staging with use of the TNM classification system for gastric adenocarcinoma, as described in the eighth edition of the AJCC Cancer Staging Manual, are briefly discussed. Accurate radiologic assessment of gastric adenocarcinoma requires identification of perigastric ligament infiltration, regional and metastatic nodal disease, and direct and metastatic organ involvement, all of which directly affect tumor staging, treatment, and prognosis. ©RSNA, 2019.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30951438     DOI: 10.1148/rg.2019180113

Source DB:  PubMed          Journal:  Radiographics        ISSN: 0271-5333            Impact factor:   5.333


  6 in total

1.  Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study.

Authors:  Hyung-Don Kim; Jong Seok Lee; Young Soo Park; Jeong Hwan Yook; Sung Hoon Noh; Young-Kyu Park; Young-Woo Kim; Sang Cheul Oh; Jong Gwang Kim; Min-Hee Ryu; Jae-Ho Cheong; HyunKi Kim; Joon Seok Lim; Jae-Hyuk Lee; Suk Hee Heo; Jin Young Kim; Mi Hwa Heo; Young Iee Park; In-Ho Kim; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2022-08-03       Impact factor: 7.701

2.  Comparison of Diagnostic Efficacy of [68Ga]Ga-FAPI-04 and [18F]FDG PET/CT for Staging and Restaging of Gastric Cancer.

Authors:  Shumao Zhang; Wei Wang; Tingting Xu; Haoyuan Ding; Yi Li; Huipan Liu; Yinxue Huang; Lin Liu; Tao Du; Yan Zhao; Yue Chen; Lin Qiu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

3.  Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study.

Authors:  Hyung-Don Kim; Jong Seok Lee; Jeong Hwan Yook; Min-Hee Ryu; Young-Kyu Park; Jin Young Kim; Young-Woo Kim; Sang Cheul Oh; Jong Gwang Kim; Jae-Ho Cheong; Oh Jeong; Sung Hoon Noh; Yoon-Koo Kang
Journal:  Gastric Cancer       Date:  2021-09-02       Impact factor: 7.370

4.  Mechanism of metastasis to the spermatic cord and testis from advanced gastric cancer: a case report.

Authors:  Soyoung Park; Sung Kyoung Moon; Joo Won Lim
Journal:  BMC Gastroenterol       Date:  2020-04-20       Impact factor: 3.067

Review 5.  Isolated brachioradialis metastasis of gastric adenocarcinoma after R0 resection.

Authors:  Elizabeth Jacob; Levi Smucker; Ryan Crouse; Ayana Allard-Picou
Journal:  World J Surg Oncol       Date:  2021-03-20       Impact factor: 2.754

6.  NOL6 Regulates the Proliferation and Apoptosis of Gastric Cancer Cells via Regulating TP53I3, CDK4 and MCM7 Expression.

Authors:  Lei He; Xiaohan Qian; Pingping Ge; Dong Fan; Xiang Ma; Qiong Wu; Jin Sun; Lihua Yang; Jian Shen; Lijian Xu
Journal:  Front Oncol       Date:  2022-04-12       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.